Current and Future Treatment Options for Eosinophilic Granulomatosis With Polyangiitis

Opinion statement Purpose of review This review aims to give an overview of efficacy and safety of the therapeutic options for eosinophilic granulomatosis with polyangiitis (EGPA). Recent findings There are few current treatments beyond glucocorticoids for the successful induction and maintenance of...

Full description

Saved in:
Bibliographic Details
Published in:Current treatment options in rheumatology 2017, Vol.3 (4), p.193-206
Main Authors: Berti, Alvise, Specks, Ulrich, Keogh, Karina A., Cornec, Divi
Format: Article
Language:English
Subjects:
Medicine
Medicine & Public Health
Rheumatology
Section Editors
Topical Collection on Vasculitis
Vasculitis (C Pagnoux and M Walsh
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Opinion statement Purpose of review This review aims to give an overview of efficacy and safety of the therapeutic options for eosinophilic granulomatosis with polyangiitis (EGPA). Recent findings There are few current treatments beyond glucocorticoids for the successful induction and maintenance of remission in EGPA, and glucocorticoids remain the cornerstone of treatment. Life-threatening manifestations likely benefit from the addition of cytotoxic agents, although results of studies investigating cyclophosphamide or azathioprine have shown mixed efficacy results and high adverse event rates. More recently, targeted therapies including rituximab and mepolizumab have shown encouraging results. Since bronchial asthma often persists beyond the control of vasculitis disease manifestations, inhaled respiratory therapy and a multispecialty management approach are advocated. Summary EGPA has been the subject of very few randomized controlled trials. Glucocorticoids remain the cornerstone of treatment. Among others, evidence of efficacy for mepolizumab and rituximab is accumulating. The optimization of asthma control is recommended.
ISSN:2198-6002
2198-6002
DOI:10.1007/s40674-017-0073-z